AdFalciVax

India is making significant strides in public health with the development of AdFalciVax, a multi-stage malaria vaccine candidate. This indigenous recombinant chimeric vaccine is designed to offer protection against human infection and reduce community transmission of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria.

Key Highlights of AdFalciVax:

• Targeting Multiple Stages: AdFalciVax is unique as it is the first indigenous recombinant chimeric malaria vaccine that specifically targets two critical stages of the malaria parasite’s life cycle. This multi-stage approach aims for broader and more effective protection.
• Collaborative Development: The vaccine is being developed through a collaborative effort led by the Indian Council of Medical Research (ICMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII).
• Promising Preclinical Efficacy: AdFalciVax has demonstrated promising efficacy in preclinical trials, indicating its potential as a viable vaccine candidate.
• “Make in India” Initiative: The development of AdFalciVax aligns with the Indian government’s “Make in India” initiative, promoting self-reliance and local innovation in critical healthcare solutions.
• Accessibility and Licensing: ICMR plans to license the technology to eligible organizations and manufacturers under non-exclusive agreements. This strategy aims to ensure wider accessibility of the vaccine and maximize its public health benefits once it’s ready.
• Current Status: Currently, AdFalciVax is in its early research and development phases and is not yet available for clinical use or commercialization.

Source: AIR